0001326190false00013261902023-09-282023-09-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 28, 2023

ALTIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware

 

001-32587

 

20-2726770

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

910 Clopper Road, Suite 201S

Gaithersburg, Maryland

20878

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number including area code: (240) 654-1450

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.0001 per share

ALT

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On September 28, 2023, Altimmune, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”). As of August 11, 2023, the record date for the 2023 Annual Meeting, there were 52,686,426 shares of the Company’s common stock outstanding and entitled to vote at the 2023 Annual Meeting. A total of 34,561,978 shares of common stock were present or represented by proxy at the 2023 Annual Meeting, representing 65.6% of the issued and outstanding shares entitled to vote at the meeting, representing a quorum. The proposals voted upon and the final results of the vote were as follows:

Proposal No. 1: Election of Directors. The results were as follows:

    

Broker

Director

For

Withhold

Non-Votes

Mitchel Sayare, Ph.D., Chairman

21,844,990

 

316,470

 

12,400,518

Vipin K. Garg, Ph.D.

21,885,151

 

276,309

 

12,400,518

David J. Drutz, M.D.

19,880,376

 

2,281,084

 

12,400,518

John M. Gill

21,588,792

 

572,668

 

12,400,518

Philip L. Hodges

21,810,125

 

351,335

 

12,400,518

Diane Jorkasky, M.D.

21,824,133

 

337,327

 

12,400,518

Wayne Pisano

19,385,875

 

2,775,585

 

12,400,518

Klaus O. Schafer, M.D., MPH

 

21,823,016

 

338,444

 

12,400,518

Catherine Sohn, Pharm D

 

21,912,287

 

249,173

 

12,400,518

Proposal No. 2: Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The results were as follows:

For

Against

Abstain

34,318,768

153,149

 

90,061

Proposal No. 3: Advisory vote on the Compensation of the Company’s named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “say-on-pay” proposal). The results were as follows:

For

Against

Abstain

Broker Non-Votes

16,834,432

5,221,648

105,380

 

12,400,518

Proposal No. 4: Advisory vote on the frequency with which the Company will hold a non-binding, advisory vote on the compensation of its named executive officers as disclosed in the Proxy Statement pursuant to the SEC’s compensation rules (referred to as the “frequency of say-on-pay” proposal). The results were as follows:

1 Year

2 Years

3 Years

Abstain

Broker Non-Votes

21,595,590

80,595

 

352,096

 

133,179

 

12,400,518

Based on the votes set forth above, the Company’s stockholders approved, on a non-binding, advisory basis, a frequency of One Year for the non-binding, advisory vote on the compensation of the Company’s named executive officers. The Board of Directors considered these voting results and other factors, and has determined that the Company will hold future advisory votes on its executive compensation on an annual basis.

Proposal No. 5: Vote to authorize the adjournment of the 2023 Annual Meeting to enable the Board of Directors to solicit additional proxies. The results were as follows:

For

Against

Abstain

27,712,554

6,744,992

 

104,432

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALTIMMUNE, INC.

By:

 

/s/ Richard Eisenstadt

 

Name: Richard Eisenstadt

 

Title: Chief Financial Officer

Dated: September 28, 2023

v3.23.3
Document and Entity Information
Sep. 28, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Sep. 28, 2023
Securities Act File Number 001-32587
Entity Registrant Name ALTIMMUNE, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 20-2726770
Entity Address, State or Province MD
Entity Address, Address Line One 910 Clopper Road
Entity Address, Address Line Two Suite 201S
Entity Address, City or Town Gaithersburg
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 654-1450
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol ALT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001326190
Amendment Flag false
Pre-commencement Issuer Tender Offer false
Pre-commencement Tender Offer false
Soliciting Material false
Written Communications false
v3.23.3
N-2
Sep. 28, 2023
Cover [Abstract]  
Entity Central Index Key 0001326190
Amendment Flag false
Securities Act File Number 001-32587
Document Type 8-K
Entity Registrant Name ALTIMMUNE, INC.
Entity Address, Address Line One 910 Clopper Road
Entity Address, Address Line Two Suite 201S
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 654-1450
Entity Emerging Growth Company false

Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Altimmune
Altimmune (NASDAQ:ALT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Altimmune